Zhang et al. found that transducing-like (β) receptor 1 (tbl1xr1) was overexpressed in NSCLC and promoted cancer progression by regulating the MEK and Akt signaling pathways through its master regulator c-MET, knockdown of tbl1xr1 by CRISPR/Cas9 in A549 and H460 cell lines resulted in an increase in the number of cells in G0/G1 phase, inhibited cell proliferation and migration, and promoted apoptosis with a concomitant increase in sensitivity to cisplatin (Zhang T. et al., 2020). This evidence concerns the gene TBL1XR1 and non-small cell lung carcinoma.